Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | FES | P07332 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | FRK | P42685 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.44 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.44 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.44 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.44 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.44 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31635975 | 0.87 | CDK2 (0.46) | PLK4AURKAMAP4K4FESFGFR1 | |
| SCHEMBL1516742 | 0.87 | CDK2 (0.46) | PLK4AURKAMAP4K4FESFGFR1 | |
| SCHEMBL7520159 | 0.87 | AURKA (0.46) | PLK4AURKAMAP4K4FESFGFR1 | |
| SCHEMBL9888004 | 0.85 | CDK2 (0.44) | PLK4AURKAMAP4K4FESFGFR1 | |
| SCHEMBL12707244 | 0.83 | ITK (0.43) | PLK4AURKAMAP4K4FESFGFR1 | |
| SCHEMBL1516568 | 0.83 | DYRK1A (0.48) | PLK4AURKAMAP4K4FESFGFR1 | |
| SCHEMBL28046056 | 0.83 | BRAF (0.53) | PLK4AURKAMAP4K4FESFGFR1 | |
| SCHEMBL4828101 | 0.83 | AURKA (0.54) | PLK4AURKAMAP4K4FESFGFR1 | |
| SCHEMBL1516649 | 0.82 | BRAF (0.40) | PLK4AURKAMAP4K4FESFGFR1 | |
| SCHEMBL19997257 | 0.82 | BRAF (0.52) | PLK4AURKAMAP4K4FESFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245355-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2011-09-08 | — | — | US | disclosed |
| CN-102171210-A | Imidazopyridin-2-one derivatives | DAIICHI SANKYO CO LTD | 2011-08-31 | — | — | CN | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| EP-1749829-B1 | JNK inhibitors | EISAI R&D MAN CO LTD (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | NFKBIA, CHUK, MAP3K1 | PLK4 1567/4885AURKA 2232/4885MAP4K4 87/4885 |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MKI67, TYMP, TK2 | PLK4 176/4885AURKA 431/4885MAP4K4 572/4885 |
| US-20110218198-A1 | Pyrrolopyridinylpyrimidin-2-ylamine derivatives | MKI67, CCNT1, CCNI | PLK4 458/4885AURKA 786/4885MAP4K4 1063/4885 |
| US-20130245355-A1 | 3-HETARYL-SUBSTITUTED PYRROLO[2,3 B]PYRIDINE DERIVATIVES AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | PLK4 214/4885AURKA 1072/4885MAP4K4 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.